[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IN2014KN01715A - - Google Patents

Info

Publication number
IN2014KN01715A
IN2014KN01715A IN1715KON2014A IN2014KN01715A IN 2014KN01715 A IN2014KN01715 A IN 2014KN01715A IN 1715KON2014 A IN1715KON2014 A IN 1715KON2014A IN 2014KN01715 A IN2014KN01715 A IN 2014KN01715A
Authority
IN
India
Prior art keywords
antibody
amino acid
acid sequence
cancer
fragment
Prior art date
Application number
Inventor
Fumiyoshi Okano
Takanori Saito
Takayoshi Ido
Yoshitaka Minamida
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of IN2014KN01715A publication Critical patent/IN2014KN01715A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Endocrinology (AREA)

Abstract

The present invention provides an antibody targeting a cancer antigen protein that is specifically expressed on the surface of a cancer cell and the use of the antibody as a therapeutic and/or prophylactic agent for cancer. More specifically the present invention provides: an antibody or a fragment thereof that has an immunological reactivity with a CAPRIN 1 partial polypeptide comprising an amino acid sequence represented by SEQ ID NO:5 or an amino acid sequence having a sequence identity of 80% or greater with said amino acid sequence; and a medicinal composition for treating and/or preventing cancer said medicinal composition being characterized by comprising the aforesaid antibody or a fragment thereof as the active ingredient.
IN1715KON2014 2012-02-21 2013-02-21 IN2014KN01715A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012035238 2012-02-21
PCT/JP2013/054403 WO2013125654A1 (en) 2012-02-21 2013-02-21 Medicinal composition for treating and/or preventing cancer

Publications (1)

Publication Number Publication Date
IN2014KN01715A true IN2014KN01715A (en) 2015-10-23

Family

ID=49005831

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1715KON2014 IN2014KN01715A (en) 2012-02-21 2013-02-21

Country Status (17)

Country Link
US (1) US9573993B2 (en)
EP (1) EP2818483B1 (en)
JP (1) JP6187256B2 (en)
KR (1) KR102005786B1 (en)
CN (1) CN104114582B (en)
AU (1) AU2013223161B2 (en)
BR (1) BR112014021102A2 (en)
CA (1) CA2864869C (en)
DK (1) DK2818483T3 (en)
ES (1) ES2643241T3 (en)
HU (1) HUE034736T2 (en)
IN (1) IN2014KN01715A (en)
MX (1) MX357505B (en)
PL (1) PL2818483T3 (en)
PT (1) PT2818483T (en)
RU (1) RU2631804C2 (en)
WO (1) WO2013125654A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2498819C2 (en) * 2008-08-05 2013-11-20 Торэй Индастриз, Инк. Pharmaceutical composition for treating and preventing malignant growths
DK2733492T3 (en) 2008-08-05 2016-04-25 Toray Industries Method for detection of cancer
BR112012018949A2 (en) * 2010-02-04 2020-09-01 Toray Industries PHARMACEUTICAL COMPOSITIONS, ANTIBODIES, PHARMACEUTICAL COMBINATION, METHODS FOR THE TREATMENT AND / OR PREVENTION OF CANCER, USES OF A PHARMACEUTICAL COMPOSITION, USE OF AN ANTIBODY AND USE OF A PHARMACEUTICAL COMBINATION
BR112014002616B1 (en) 2011-08-04 2022-01-18 Toray Industries, Inc METHOD TO DETECT PANCREATIC CANCER
ES2609846T3 (en) * 2011-08-04 2017-04-24 Toray Industries, Inc. Pharmaceutical composition for the treatment and / or prevention of pancreatic cancer
MX357505B (en) 2012-02-21 2018-07-12 Toray Industries Medicinal composition for treating and/or preventing cancer.
CA2869120C (en) * 2012-03-30 2023-05-23 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
PL2832366T3 (en) 2012-03-30 2018-04-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
JP6244911B2 (en) 2012-07-19 2017-12-13 東レ株式会社 Cancer detection method
PT2876447T (en) 2012-07-19 2020-02-03 Toray Industries Method for detecting cancer
KR102134088B1 (en) 2012-08-24 2020-07-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
RU2678138C2 (en) 2013-08-09 2019-01-23 Торэй Индастриз, Инк. Pharmaceutical composition for treatment and/or prevention of cancer
SG11201700787XA (en) * 2014-08-07 2017-02-27 Sloan Kettering Inst Cancer Anti-ceramide antibodies
CN109069628A (en) * 2016-01-14 2018-12-21 Bps生物科学有限公司 Anti- PD-1 antibody and application thereof
WO2017152088A1 (en) 2016-03-04 2017-09-08 JN Biosciences, LLC Antibodies to tigit
EP3474854A4 (en) 2016-06-27 2020-02-19 The Regents of The University of California Cancer treatment combinations
CN115317603A (en) 2016-07-07 2022-11-11 小利兰·斯坦福大学托管委员会 Antibody adjuvant conjugates
RU2766586C2 (en) * 2016-10-28 2022-03-15 Торэй Индастриз, Инк. Pharmaceutical composition for treatment and/or prevention of malignant tumor
CN111936164B (en) 2018-03-30 2024-09-17 东丽株式会社 Pharmaceutical composition for treating and/or preventing cancer
CN113993549A (en) 2019-03-15 2022-01-28 博尔特生物治疗药物有限公司 Immunoconjugates targeting HER2
WO2020252294A1 (en) 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
MX2022003740A (en) 2019-09-30 2022-05-02 Bolt Biotherapeutics Inc Amide-linked, aminobenzazepine immunoconjugates, and uses thereof.
BR112022007719A2 (en) 2019-10-25 2022-07-12 Bolt Biotherapeutics Inc IMMUNOCONJUGATES, BINDING COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD TO TREAT CANCER, USE OF AN IMMUNOCONJUGATE AND METHOD OF PREPARING AN IMMUNOCONJUGATE
US20230159635A1 (en) 2020-03-12 2023-05-25 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20220152309A (en) 2020-03-12 2022-11-15 도레이 카부시키가이샤 Medicines for the treatment and/or prevention of cancer
KR20220153615A (en) 2020-03-12 2022-11-18 도레이 카부시키가이샤 Medicines for the treatment and/or prevention of cancer
EP4119156A4 (en) 2020-03-12 2024-05-08 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
US20230139178A1 (en) 2020-03-12 2023-05-04 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JP2023524271A (en) 2020-05-08 2023-06-09 ボルト バイオセラピューティクス、インコーポレーテッド Elastase-substrate peptide linker immunoconjugates and uses thereof
IL298111A (en) 2020-06-02 2023-01-01 Arcus Biosciences Inc Antibodies to tigit
WO2022036101A1 (en) 2020-08-13 2022-02-17 Bolt Biotherapeutics, Inc. Pyrazoloazepine immunoconjugates, and uses thereof
EP4360648A1 (en) 2021-06-23 2024-05-01 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
MX2023014500A (en) 2021-06-23 2024-01-25 Toray Industries Medicament for treatment and/or prevention of cancer.
KR20240042416A (en) 2021-07-27 2024-04-02 도레이 카부시키가이샤 Medicines for the treatment and/or prevention of cancer
MX2024001099A (en) 2021-07-27 2024-02-23 Toray Industries Medicament for treatment and/or prevention of cancer.
JPWO2023008462A1 (en) 2021-07-27 2023-02-02
JPWO2023033129A1 (en) 2021-09-03 2023-03-09
EP4422697A1 (en) 2021-10-29 2024-09-04 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
WO2023177821A2 (en) * 2022-03-16 2023-09-21 Myeloid Therapeutics, Inc. Binding domains and methods of use thereof
WO2024173387A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
FR2761994B1 (en) 1997-04-11 1999-06-18 Centre Nat Rech Scient PREPARATION OF MEMBRANE RECEPTORS FROM EXTRACELLULAR BACULOVIRUSES
TR200101541T2 (en) 1998-04-03 2002-06-21 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF).
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
IL140845A0 (en) 1998-07-14 2002-02-10 Corixa Corp Compositions for therapy and diagnosis of prostate cancer
RU2234942C2 (en) 1998-07-14 2004-08-27 Корикса Корпорейшн Tumor polypeptide isolated from prostate and polynucleotide encoding thereof
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
AU4185100A (en) 1999-04-02 2000-10-23 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CA2388822A1 (en) 1999-10-29 2001-05-10 Human Genome Sciences, Inc. 27 human secreted proteins
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CZ20023567A3 (en) 2000-03-29 2003-11-12 Corixa Corporation Compounds and methods for therapy and diagnosis of lung carcinoma
AU2002239422B2 (en) 2000-11-30 2006-12-07 E. R. Squibb & Sons, L.L.C. Transgenic transchromosomal rodents for making human antibodies
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (en) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Method for treating the cases of malignant tumors containing b-cells with a combination of applications related to antibodies reducing b-cells number and with immunomodulating antibodies
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
JP4115281B2 (en) 2001-05-11 2008-07-09 キリンファーマ株式会社 Human artificial chromosome containing human antibody λ light chain gene, and non-human animal containing the human artificial chromosome capable of offspring transmission
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
JP2004535202A (en) 2001-07-17 2004-11-25 リサーチ　ディベロップメント　ファンデーション Therapeutic agents containing pro-apoptotic proteins
RU2319709C2 (en) 2001-07-17 2008-03-20 Рисерч Дивелопмент Фаундейшн Proapoptosis proteins-containing therapeutic agents
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP2388265A1 (en) 2002-02-22 2011-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
WO2004047728A2 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
EP1629119A2 (en) 2003-04-29 2006-03-01 Wyeth Methods for diagnosing aml and mds by differential gene expression
JP2007516693A (en) 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン Compositions and methods for the treatment and diagnosis of cancer
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
EP2361929A1 (en) 2004-01-26 2011-08-31 Debiovision Inc. Neoplasm-specific polypeptides and their use
WO2005090407A1 (en) 2004-03-19 2005-09-29 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
PL1730191T3 (en) 2004-03-30 2011-12-30 Glaxo Group Ltd Immunoglobulin binding hosm
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
WO2006078307A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
AU2006214105A1 (en) 2005-02-18 2006-08-24 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
US7510842B2 (en) 2005-03-11 2009-03-31 Vermilllion, Inc. Biomarker for ovarian and endometrial cancer: hepcidin
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
CA2635616A1 (en) 2006-01-05 2007-07-19 Carlo M. Croce Microrna expression abnormalities in pancreatic endocrine and acinar tumors
EP1991701A4 (en) 2006-02-14 2010-03-17 Dana Farber Cancer Inst Inc Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7615349B2 (en) 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
CN106053833B (en) 2007-10-25 2018-12-25 东丽株式会社 The detection method of cancer
JP5663834B2 (en) 2008-03-14 2015-02-04 東ソー株式会社 Method for producing recombinant antibody
AR070865A1 (en) 2008-03-18 2010-05-12 Genentech Inc COMBINATIONS OF AN ANTIBODY-ANTI-HER2 PHARMACO AND CHEMOTHERAPEUTIC AGENTS AND METHODS OF USE
KR101669827B1 (en) 2008-08-05 2016-10-27 도레이 카부시키가이샤 Immunity inducer
RU2498819C2 (en) * 2008-08-05 2013-11-20 Торэй Индастриз, Инк. Pharmaceutical composition for treating and preventing malignant growths
DK2733492T3 (en) 2008-08-05 2016-04-25 Toray Industries Method for detection of cancer
EA032728B1 (en) 2009-08-19 2019-07-31 Мерк Патент Гмбх Antibodies for the detection of integrin complexes in ffpe material
MX2012003404A (en) 2009-09-22 2012-09-12 Volker Sandig Process for producing molecules containing specialized glycan structures.
BR112012018949A2 (en) 2010-02-04 2020-09-01 Toray Industries PHARMACEUTICAL COMPOSITIONS, ANTIBODIES, PHARMACEUTICAL COMBINATION, METHODS FOR THE TREATMENT AND / OR PREVENTION OF CANCER, USES OF A PHARMACEUTICAL COMPOSITION, USE OF AN ANTIBODY AND USE OF A PHARMACEUTICAL COMBINATION
RU2624029C2 (en) 2010-02-04 2017-06-30 Торэй Индастриз, Инк. Drugs for cancer treatment and/or prevention
DK2532364T3 (en) 2010-02-04 2016-08-15 Toray Industries PHARMACEUTICAL COMPOSITION CONTAINING ANTI CAPRIN-1 ANTIBODIES FOR TREATMENT AND / OR PREVENTION OF CANCER
DK2532365T3 (en) 2010-02-04 2016-08-15 Toray Industries PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF CANCER
HUE030742T2 (en) 2010-02-04 2017-06-28 Toray Industries Pharmaceutical composition for treating and/or preventing cancer
RU2567657C2 (en) * 2010-02-04 2015-11-10 Торэй Индастриз, Инк. Pharmaceutical composition for treating and/or preventing cancer
WO2012005550A2 (en) 2010-07-08 2012-01-12 강원대학교산학협력단 Pharmaceutical composition for treating gallbladder carcinoma, and method for inhibiting growth and metastasis of gallbladder carcinoma and treating gallbladder carcinoma, using same
KR101576174B1 (en) 2010-07-26 2015-12-09 르 라보레또레 쎄르비에르 Methods and compositions for liver cancer therapy
JP4937389B2 (en) 2010-08-11 2012-05-23 三協技研工業株式会社 Solid-liquid separation method and solid-liquid separation device
PT2740793T (en) 2011-08-04 2018-02-23 Toray Industries Drug composition for cancer treatment and/or prevention
BR112014002616B1 (en) 2011-08-04 2022-01-18 Toray Industries, Inc METHOD TO DETECT PANCREATIC CANCER
ES2609846T3 (en) 2011-08-04 2017-04-24 Toray Industries, Inc. Pharmaceutical composition for the treatment and / or prevention of pancreatic cancer
DK2740794T3 (en) 2011-08-04 2018-06-14 Toray Industries PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR CANCER PREVENTION
ES2618026T3 (en) 2011-08-04 2017-06-20 Toray Industries, Inc. Pharmacological composition for the treatment and / or prevention of cancer
KR101980554B1 (en) 2011-08-04 2019-05-21 도레이 카부시키가이샤 Cancer treatment and/or prevention drug composition
ES2634249T3 (en) 2011-08-04 2017-09-27 Toray Industries, Inc. Pharmaceutical composition for the treatment and / or prophylaxis of cancer
BR112014021103A2 (en) 2012-02-21 2019-10-15 Toray Industries, Inc ANTIBODY, PHARMACEUTICAL COMPOSITION, COMBINATION DRUG, DNA, METHOD OF TREATMENT AND USE OF ANTIBODY
MX363136B (en) 2012-02-21 2019-03-12 Toray Industries Pharmaceutical composition for treatment and/or prevention of cancer.
MX357505B (en) 2012-02-21 2018-07-12 Toray Industries Medicinal composition for treating and/or preventing cancer.
EP2818482B1 (en) 2012-02-21 2019-05-22 Toray Industries, Inc. Pharmaceutical composition for treatment of cancer
PL2832366T3 (en) * 2012-03-30 2018-04-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
CA2869120C (en) 2012-03-30 2023-05-23 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
US9192530B2 (en) 2013-07-29 2015-11-24 Nacco Materials Handling Group, Inc. Moveable seat

Also Published As

Publication number Publication date
RU2014138041A (en) 2016-04-10
EP2818483A1 (en) 2014-12-31
PT2818483T (en) 2017-10-09
KR20140130669A (en) 2014-11-11
EP2818483B1 (en) 2017-08-02
BR112014021102A2 (en) 2021-12-28
JPWO2013125654A1 (en) 2015-07-30
PL2818483T3 (en) 2018-01-31
CA2864869A1 (en) 2013-08-29
JP6187256B2 (en) 2017-08-30
HUE034736T2 (en) 2018-02-28
AU2013223161A1 (en) 2014-09-11
AU2013223161B2 (en) 2017-10-19
US9573993B2 (en) 2017-02-21
CN104114582B (en) 2018-12-21
MX357505B (en) 2018-07-12
WO2013125654A1 (en) 2013-08-29
ES2643241T3 (en) 2017-11-21
DK2818483T3 (en) 2017-10-23
RU2631804C2 (en) 2017-09-26
KR102005786B1 (en) 2019-07-31
CN104114582A (en) 2014-10-22
MX2014009746A (en) 2014-11-14
US20150050283A1 (en) 2015-02-19
CA2864869C (en) 2021-10-19
EP2818483A4 (en) 2015-09-02

Similar Documents

Publication Publication Date Title
IN2014KN01715A (en)
MX2014001375A (en) Pharmaceutical composition for treatment and/or prophylaxis of cancer.
IN2014KN01713A (en)
MX2012008999A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX2012008998A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX342291B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
IN2014KN01714A (en)
IN2014KN01716A (en)
MX340016B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
MX2014001371A (en) Pharmaceutical composition for treatment and/or prophylaxis of cancer.
MX2014001372A (en) Pharmaceutical composition for treatment and/or prevention of pancreatic cancer.
MX358224B (en) Pharmaceutical composition for treatment and/or prevention of liver cancer.
MX340017B (en) Medicinal composition for treating and/or preventing cancer.
MX2014001374A (en) Cancer treatment and/or prevention drug composition.
MX357965B (en) Pharmaceutical composition for treatment and/or prevention of gall bladder cancer.
EA201490809A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NON-EFFECTIVE ERYTHROPOESIS
MX2014001370A (en) Cancer treatment and/or prevention drug composition.
NZ705370A (en) Fcγriib-specific fc region variant
IN2014CN04498A (en)
EA201590601A1 (en) APPLICATION OF PEDF-DERIVED POLYPEPTIDES FOR THE TREATMENT OF OSTEOARTHRITIS
EP2552462A4 (en) Ccn3 peptides and analogs thereof for therapeutic use
MX2017013480A (en) Pharmaceutical composition for treating and/or preventing cancer.
IN2014DN07875A (en)
MX2018011133A (en) Pharmaceutical composition for treating and/or preventing cancer.